CA
NZ
UK
AU
IND
US
…
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -6.50M | -8.38M | -8.38M | -4.66M | -0.62M |
| Net income | -6.50M | -8.38M | -8.38M | -4.66M | -0.62M |
| Selling general administrative | 5.79M | 8.17M | 6.94M | 4.40M | 0.47M |
| Selling and marketing expenses | 0.77M | 0.18M | 0.16M | 0.09M | 0.10M |
| Gross profit | -0.38M | 0.03M | 0.02M | 0.00M | 0.00M |
| Reconciled depreciation | 0.40M | 0.28M | 0.05M | 0.02M | 0.02M |
| Ebit | -6.48M | -8.36M | -1.64M | -4.44M | -0.62M |
| Ebitda | -6.09M | -8.09M | -1.53M | -4.42M | -0.60M |
| Depreciation and amortization | 0.40M | 0.28M | 0.11M | 0.02M | 0.02M |
| Operating income | -6.48M | -8.37M | -7.24M | -4.55M | -0.62M |
| Other operating expenses | 6.50M | 8.40M | 7.26M | 4.55M | 0.62M |
| Interest expense | 0.01M | 0.02M | 6.74M | - | - |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 0.00M | 0.00M | 0.00M | - | - |
| Net interest income | -0.01M | -0.02M | -6.73M | - | - |
| Income tax expense | - | - | - | 0.11M | - |
| Total revenue | 0.01M | 0.03M | 0.02M | 0.00M | 0.00M |
| Total operating expenses | 6.10M | 8.40M | 7.26M | 4.55M | 0.62M |
| Cost of revenue | 0.40M | 0.28M | 0.11M | - | - |
| Total other income expense net | -0.01M | -0.02M | -1.13M | -0.11M | - |
| Net income from continuing ops | -6.50M | -8.38M | -9.37M | -4.66M | -0.62M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 7.77M | 10.62M | 4.46M | 6.25M | 1.10M |
| Intangible assets | 0.87M | 0.71M | 0.54M | 0.36M | 0.30M |
| Other current assets | 0.80M | 0.94M | 1.22M | 1.77M | 0.04M |
| Total liab | 0.79M | 1.06M | 1.50M | 1.95M | 0.03M |
| Total stockholder equity | 6.97M | 9.56M | 2.96M | 4.30M | 1.07M |
| Other current liab | - | 0.54M | 0.22M | - | - |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -29.25M | -22.75M | -14.37M | -5.99M | -1.33M |
| Good will | - | 0.70M | - | - | - |
| Cash | 5.11M | 7.83M | 1.28M | 4.12M | 0.51M |
| Total current liabilities | 0.60M | 0.63M | 0.84M | 0.85M | 0.03M |
| Current deferred revenue | - | - | -0.22M | - | - |
| Net debt | -4.42M | -6.86M | -0.02M | -4.12M | -0.51M |
| Short term debt | 0.51M | 0.54M | 0.60M | - | - |
| Short long term debt | 0.27M | 0.31M | - | - | - |
| Short long term debt total | 0.70M | 0.97M | 1.26M | - | - |
| Other stockholder equity | 36.22M | 32.31M | 17.33M | 10.29M | 2.40M |
| Total current assets | 5.92M | 8.79M | 2.77M | 5.89M | 0.80M |
| Net receivables | 0.01M | 0.02M | 0.26M | 0.00M | 0.00M |
| Inventory | - | - | - | - | 0.25M |
| Accounts payable | 0.10M | 0.09M | 0.24M | 1.10M | - |
| Accumulated other comprehensive income | - | 0.00M | 0.00M | - | - |
| Non currrent assets other | 0.01M | 0.01M | 0.01M | 0.00M | - |
| Non current assets total | 1.85M | 1.82M | 1.70M | 0.36M | 0.30M |
| Capital lease obligations | 0.43M | 0.66M | 0.89M | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.40M | -0.23M | -0.37M | -0.36M |
| Total cashflows from investing activities | -0.42M | -0.40M | -0.79M | - | - |
| Net borrowings | - | 0.00M | 4.50M | - | - |
| Total cash from financing activities | 3.43M | 11.94M | 3.63M | 9.06M | 1.23M |
| Net income | -6.50M | -8.38M | -8.38M | -4.66M | -0.62M |
| Change in cash | -2.72M | 6.54M | -2.83M | 3.60M | 0.28M |
| Begin period cash flow | 7.83M | 1.28M | 4.12M | 0.51M | 0.24M |
| End period cash flow | 5.11M | 7.83M | 1.28M | 4.12M | 0.51M |
| Total cash from operating activities | -5.73M | -4.99M | -5.67M | -5.09M | -0.59M |
| Issuance of capital stock | 3.80M | 12.55M | 0.00M | 11.99M | 1.12M |
| Depreciation | 0.16M | 0.28M | 0.11M | 0.02M | 0.02M |
| Other cashflows from investing activities | -0.23M | -0.19M | -0.20M | - | - |
| Change to inventory | - | - | 0.00M | - | - |
| Change to account receivables | 0.01M | -0.01M | -0.00M | 0.00M | -0.00M |
| Other cashflows from financing activities | 3.43M | -0.61M | -0.87M | -2.92M | 0.10M |
| Capital expenditures | 0.19M | 0.40M | 0.79M | 0.08M | 0.11M |
| Change in working capital | 0.26M | 0.52M | 0.21M | -0.56M | -0.04M |
| Stock based compensation | 0.11M | 2.59M | 1.28M | 0.00M | 0.06M |
| Other non cash items | 0.24M | 0.00M | 1.10M | 0.11M | -0.00M |
| Free cash flow | -5.91M | -5.40M | -6.47M | -5.17M | -0.70M |
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| DOGEF Orsted A/S |
- -% |
19.77 | 28.82 | 0.66 | 6.50 | 0.07 |
| TBB AT&T Inc. 5.35% GLB NTS 66 |
-0.01 0.06% |
17.62 | 4.60 | - | - | - |
| CCZ Comcast Holdings Corp |
- -% |
62.55 | 55.07 | - | - | - |
| STMZF Scottish Mortgage Investment Trust PLC |
- -% |
20.00 | - | - | 2.56 | - |
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
| Name | Title | Year Born |
|---|---|---|
| Dr. Meeshanthini Dogan Ph.D. | CEO & Director | 1989 |
| Ms. Elisa Michael Luqman J.D., M.B.A. | CFO & Director | 1964 |
| Dr. Robert A. Philibert M.D., Ph.D. | Chief Medical Officer & Director | 1962 |
| Khullani Abdullah | VP of Revenue & Strategy | NA |
| Dr. Meeshanthini V. Dogan Ph.D. | Co-Founder, CEO & Director | 1989 |
| Ms. Elisa Michael Luqman Esq., J.D., M.B.A. | Chief Financial Officer | 1964 |
| Dr. Robert A. Philibert M.D., Ph.D. | Co-Founder, Chief Medical Officer & Director | 1962 |
| Mr. Timur Dogan Ph.D. | Chief Technology Officer | 1988 |
| Ms. Khullani Abdullahi J.D. | Vice President of Revenue & Strategy | 1984 |
| Ms. Elisa Michael Luqman Esq., J.D., M.B.A. | CFO & Principal Accounting Officer | 1964 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.59%
Communication Services
+0.05%
Consumer Cyclical
+0.14%
Consumer Defensive
-0.43%
Energy
-0.03%
Financial Services
+0.19%
Financials
-0.35%
Healthcare
+1.05%
Industrials
+0.67%
Real Estate
-0.25%
Technology
+1.31%
Utilities
+0.32%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...